Epstein Secrets

. The New York Post <https://nypost.corn/2020/07/30/johnson-johnson-starts-human-vaccine-trials-after-monkey- study/> (7/30, O'Neill, 4.57M) reports Johnson & Johnson began human trials of its experimental COVID-19 vaccine on Thursday, "after the shots already proved successful in protecting monkeys, the drugmaker

d-July." The Hill <https://thehill.corn/homenews/house/509823-house-ethics-panel-recommends-50000-fine-for-rep- schweikerts-campaign-finance> (7/30, Marcos, 2.98M) recounts that "an investigative report released by the Ethics Committee concluded that Schweikert, who has served in the House since 2011, v

ication, 8.41M) also have reports. J&J Says It Should Have Enough Doses For More Than 20M By End Of March. The Hill (2/22, Sullivan, 5.69M) reports Johnson & Johnson said Monday that it "plans to have enough doses of its vaccine for more than 20 million Americans by the end of March" if its vaccine is authorized

enues of inquiry that might steer the panel in certain directions, as opposed to allowing panelists to determine their own course." The Hill (2/22, Marcos, 5.69M) provides similar coverage. EFTA00148041 Capitol Police Officer Discusses Attack On Capitol. In an exclusive, the ABC News (2/22, Thomas,

rapid cure for a pathogen like covid-19 for years." Johnson & Johnson Starts Human Vaccine Trials. The New York Post (7/30, O'Neill, 4.57M) reports Johnson & Johnson began human trials of its experimental COVID-19 vaccine on Thursday, "after the shots already proved successful in protecting monkeys, the drugmake

ation to face him in November; among them, Hiral Tipirneni had a $1 million cash-on-hand advantage over Schweikert as of mid-July." The Hill (7/30, Marcos, 2.98M) recounts that "an investigative report released by the Ethics Committee concluded that Schweikert, who has served in the House since 2011, v

rapid cure for a pathogen like covid-19 for years." Johnson & Johnson Starts Human Vaccine Trials. The New York Post (7/30, O'Neill, 4.57M) reports Johnson & Johnson began human trials of its experimental COVID-19 vaccine on Thursday, "after the shots already proved successful in protecting monkeys, the drugmake

ation to face him in November; among them, Hiral Tipirneni had a $1 million cash-on-hand advantage over Schweikert as of mid-July." The Hill (7/30, Marcos, 2.98M) recounts that "an investigative report released by the Ethics Committee concluded that Schweikert, who has served in the House since 2011, v